Ten Years of Orthoclone OKT3 (Muromonab-CD3): A Review
Journal of Transplant Coordination · 1996
DOI: 10.1177/090591999600600304 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Transplant Coordination, 1996. Verfasst von Susan L Smith. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 89 Literaturangaben.
Abstract (Originalsprache)
Many important advances in transplantation have been made during the last decade. The introduction of Orthoclone OKT3 into clinical trials and its subsequent approval by the Food and Drug Administration in 1985 for use as an antirejection agent for renal transplantation were landmarks in the field of clinical transplantation of solid organs. In the decade since the approval of OKT3 for clinical use, much has been learned and written about OKT3. OKT3 now is considered a safe and effective agent for prophylaxis and first-line treatment of acute rejection of solid organ allografts. In this article, the development and use of OKT3 over the last 10 years, as well as the present status and future implications of immune therapy with OKT3, are reviewed.
Zitieren
APA
Smith, S. L. (1996). Ten Years of Orthoclone OKT3 (Muromonab-CD3): A Review. Journal of Transplant Coordination. https://doi.org/10.1177/090591999600600304
Vancouver
Smith SL. Ten Years of Orthoclone OKT3 (Muromonab-CD3): A Review. Journal of Transplant Coordination. 1996. doi:10.1177/090591999600600304
BibTeX
@article{Smith1996,
author = {Smith, Susan L},
title = {Ten Years of Orthoclone OKT3 (Muromonab-CD3): A Review},
journal = {Journal of Transplant Coordination},
year = {1996},
doi = {10.1177/090591999600600304}
}
EUVIMED